Last updated: 2026-10-09 16:32:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Cardio Diagnostics Holdings Inc. (CDIO) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $1.91, with a market capitalization of $5.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $7.91. This page covers its latest market performance, valuation, price trends and company information.
$5.80M | |
$1.90 | |
$255.00 | |
$0.97 | |
$1.86 | |
12.09K | |
56.72K | |
-- | |
$7.91 | |
$0.97 | |
-- | |
-- |
Cardio Diagnostics Holdings Inc. (CDIO) is currently trading at $1.91 as of 2026-10-09 16:30:00, up 2.42% ($0.04) from the previous close of $1.86
During today's regular trading session, CDIO has traded between $0.97 and $255.00, with a trading volume of 12.09K shares. The current price is near the lower end of today's range.
Over the past seven days, Cardio Diagnostics Holdings Inc. (CDIO) moved from $1.90 to $1.91, representing a gain of 0.26% ($0.01).
The stock traded between $1.85 and $2.23 during the period. The latest price is near the lower end of the 7-day range, indicating range-bound.
The average daily volume was 32.27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13.5%
CDIO is currently trading at $1.91, placing it 13.5% of the way from its 52-week low of $0.97 to its 52-week high of $7.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardio Diagnostics Holdings Inc. (CDIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.